Literature DB >> 19372551

Connexin43 pseudogene in breast cancer cells offers a novel therapeutic target.

Andrew Bier1, Irene Oviedo-Landaverde, Jing Zhao, Yael Mamane, Mustapha Kandouz, Gerald Batist.   

Abstract

Connexin43 (Cx43) is often deregulated in breast cancer tissue compared with normal adjacent tissue. Stable reexpression of Cx43 in cancer slows growth and renders the cells more sensitive to cytotoxic chemotherapeutics. Pseudogenes are often considered nonfunctional copies of DNA. The Cx43 pseudogene (PsiCx43) possesses all the features of an expressed gene and is exclusively transcribed in breast cancer cell lines and not in normal cells. PsiCx43 can be translated in vivo, and its protein exhibits growth-suppressive behavior similar to Cx43. We showed that PsiCx43 binds to the polyribosomes in breast cancer cells and that exogenous expression of PsiCx43 induces translational inhibition of Cx43. Furthermore, PsiCx43 is translated and binds more efficiently to the translational machinery than does Cx43 in an in vitro system. Following knockdown of PsiCx43 in breast cancer cells, we observed an increase in Cx43 RNA and protein. This results in increased cellular sensitivity to cytotoxic chemotherapy. Our results show that PsiCx43 acts as a posttranscriptional regulator of Cx43 in breast cancer cells, and that this represents an example of the regulation of genes by pseudogenes with potential therapeutic implications in cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372551     DOI: 10.1158/1535-7163.MCT-08-0930

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  20 in total

1.  Pseudogene-mediated posttranscriptional silencing of HMGA1 can result in insulin resistance and type 2 diabetes.

Authors:  Eusebio Chiefari; Stefania Iiritano; Francesco Paonessa; Ilaria Le Pera; Biagio Arcidiacono; Mirella Filocamo; Daniela Foti; Stephen A Liebhaber; Antonio Brunetti
Journal:  Nat Commun       Date:  2010-07-27       Impact factor: 14.919

2.  Pseudogenes: Four Decades of Discovery.

Authors:  Leonardo Salmena
Journal:  Methods Mol Biol       Date:  2021

3.  Influence of gap junction intercellular communication composed of connexin 43 on the antineoplastic effect of adriamycin in breast cancer cells.

Authors:  Guojun Jiang; Shuying Dong; Meiling Yu; Xi Han; Chao Zheng; Xiaoguang Zhu; Xuhui Tong
Journal:  Oncol Lett       Date:  2016-12-07       Impact factor: 2.967

Review 4.  Gap junctions and cancer: communicating for 50 years.

Authors:  Trond Aasen; Marc Mesnil; Christian C Naus; Paul D Lampe; Dale W Laird
Journal:  Nat Rev Cancer       Date:  2016-10-21       Impact factor: 60.716

5.  The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo.

Authors:  Florian A Karreth; Markus Reschke; Anna Ruocco; Christopher Ng; Bjoern Chapuy; Valentine Léopold; Marcela Sjoberg; Thomas M Keane; Akanksha Verma; Ugo Ala; Yvonne Tay; David Wu; Nina Seitzer; Martin Del Castillo Velasco-Herrera; Anne Bothmer; Jacqueline Fung; Fernanda Langellotto; Scott J Rodig; Olivier Elemento; Margaret A Shipp; David J Adams; Roberto Chiarle; Pier Paolo Pandolfi
Journal:  Cell       Date:  2015-04-02       Impact factor: 41.582

6.  The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer.

Authors:  H Hayashi; T Arao; Y Togashi; H Kato; Y Fujita; M A De Velasco; H Kimura; K Matsumoto; K Tanaka; I Okamoto; A Ito; Y Yamada; K Nakagawa; K Nishio
Journal:  Oncogene       Date:  2013-12-23       Impact factor: 9.867

7.  Not so pseudo anymore: pseudogenes as therapeutic targets.

Authors:  Thomas C Roberts; Kevin V Morris
Journal:  Pharmacogenomics       Date:  2013-12       Impact factor: 2.533

8.  Expressed pseudogenes in the transcriptional landscape of human cancers.

Authors:  Shanker Kalyana-Sundaram; Chandan Kumar-Sinha; Sunita Shankar; Dan R Robinson; Yi-Mi Wu; Xuhong Cao; Irfan A Asangani; Vishal Kothari; John R Prensner; Robert J Lonigro; Matthew K Iyer; Terrence Barrette; Achiraman Shanmugam; Saravana M Dhanasekaran; Nallasivam Palanisamy; Arul M Chinnaiyan
Journal:  Cell       Date:  2012-06-22       Impact factor: 41.582

9.  The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancer.

Authors:  Ivett Teleki; Tibor Krenacs; Marcell A Szasz; Janina Kulka; Barna Wichmann; Cornelia Leo; Barbel Papassotiropoulos; Cosima Riemenschnitter; Holger Moch; Zsuzsanna Varga
Journal:  BMC Cancer       Date:  2013-02-02       Impact factor: 4.430

10.  Post-transcriptional regulation of connexin43 in H-Ras-transformed cells.

Authors:  Mustapha Kandouz; Jing Zhao; Andrew Bier; Sergio Di Marco; Irene Oviedo-Landaverde; Imed-Eddine Gallouzi; Gerald Batist
Journal:  PLoS One       Date:  2013-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.